INVENTIVA: Inventiva reports its 2022 full-year results

Cash and cash equivalents at €86.7 million and short term deposits at €1 million as of December 31, 2022 compared to €86.6 million and €8.8 million, respectively as of December 31, 2021 Inventiva

Related Keywords

Tianqing ,Zhejiang ,China ,France ,Belgium ,Bourgogne ,Champagne Ardenne ,Netherlands ,Taiwan ,United States ,Russia ,Ukraine ,Chicago ,Illinois ,Paris ,France General ,New York ,Daix ,United Kingdom ,Brunswick ,Niedersachsen ,Germany ,Amsterdam ,Noord Holland ,French ,Chinese ,Aude Lepreux ,Sino Biopharm ,Pascaline Clerc ,Kempen Life Sciences Conference ,Exchange Commission On ,Company Nati ,Nasdaq ,Program On ,Chia Tai Tianqing Pharmaceutical Group ,Brunswick Group ,Patricial Bank ,Trademark Office ,Global External Affairs ,University Of Florida ,European Investment Bank ,Euronext ,Long Island City ,Euronext Paris ,Mainland China ,Hong Kong Special Administrative Region ,Macau Special Administrative Region ,Agricole Champagne Bourgogne ,United States Patent ,Non Alcoholic Fatty Liver Disease ,Investigational New Drug ,Sofinnova Partners ,Sofinnova Partner ,Greater China ,Euronext Tech Leaders ,Patient First Visit ,Life Sciences Conference ,Global Healthcare Conference ,York City ,Disease Week ,Global External ,Private Securities Litigation Reform Act ,New Drug Application ,Universal Registration Document ,Des March ,Annual Report ,Exchange Commission ,Diese Gold Aktie ,Sichern Sie ,Inventiva ,Reports ,022 ,Bull ,Ear ,Results ,